YK-11 is a steroidal selective androgen receptor modulator with a unique dual mechanism: it functions both as a partial AR agonist and as a myostatin inhibitor. Structurally derived from dihydrotestosterone (DHT) — specifically, it is a synthetic 5a-dihydrotestosterone derivative with a methylester group at the C-2 position — YK-11 occupies a pharmacological category entirely its own. Its myostatin-inhibiting property distinguishes it from every other compound in the SARM class and positions it as one of the most theoretically potent anabolic agents available in oral form.

YK-11 exerts its anabolic effects through two parallel pathways. First, it binds to the androgen receptor with selectivity for muscle tissue, initiating standard AR-mediated anabolic signaling — protein synthesis upregulation, nitrogen retention, and myonuclear accretion. Second, and uniquely, YK-11 induces the expression of follistatin in muscle cells. Follistatin is the endogenous antagonist of myostatin, the protein that genetically limits skeletal muscle growth. By upregulating follistatin, YK-11 effectively removes the biological ceiling on muscle hypertrophy — a mechanism observed in myostatin-knockout animal models, which exhibit dramatic muscular hyperplasia.

The research literature positions YK-11 as the compound of choice when researchers seek muscle growth beyond what standard AR agonism alone can deliver. In cellular studies, YK-11 induced greater follistatin expression than dihydrotestosterone itself. Anecdotal and preclinical data consistently report rapid, dense muscle gains that exceed those achievable with other SARMs at comparable doses — gains frequently described as more reminiscent of anabolic steroids than typical SARMs.

YK-11 is recommended exclusively for experienced researchers who have prior exposure to at least one SARM or anabolic compound. Its potency and steroidal backbone mean that side effects, while tissue-selective relative to traditional anabolics, are more pronounced than milder SARMs like Ostarine or ACP-105. Researchers pursuing maximum muscle mass accrual — particularly those who feel they have plateaued with standard SARMs — are the ideal candidates.

YK-11 has a short elimination half-life of approximately 6–10 hours, necessitating split dosing (twice daily) for stable plasma concentrations. It is methylated (17a-methyl), which confers oral bioavailability but introduces hepatotoxic potential similar to oral anabolic steroids — liver support supplementation (TUDCA, NAC) is strongly recommended. Testosterone suppression is moderate to significant, and PCT is considered essential following any cycle. Standard research protocols range from 5–15mg daily for 6–8 weeks. Due to its hepatotoxicity profile, cycles should not exceed 8 weeks without bloodwork monitoring.